Technical report reveals a covalent inhibitor with high selectivity and strong binding affinity for KRAS G12C.
This technical report details the identification of Z-97615-R, a novel small-molecule covalent inhibitor targeting the Switch II pocket of the KRAS G12C mutant. The discovery was facilitated by the S-NEM (Selective Non-linear Evolutionary Manifold) framework, which utilizes a 70-dimensional topological resonance mapping process to navigate an astronomical search space of 2⁷⁰ discrete conformational states. Key Findings: Lead Compound: Z-97615-R Binding Affinity (ΔG): -9.50 kcal/mol Resonance Parity (P): 0.9998x Selectivity: 94.2% (G12C Covalent) SMILES: CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F This work is released into the public domain to accelerate global oncological research and ensure unrestricted access to potential therapeutic scaffolds.
No takes yet. Share an insight, caveat, or question.
Darius Puzinas (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: